Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

McKesson Gets IBD Stock Rating Upgrade

The IBD SmartSelect Composite Rating for McKesson increased from 93 to 96 Tuesday.

The upgrade means the stock is now outpacing 96% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.

McKesson is trading about 4% above a 632.59 entry from a cup with handle.

Looking For The Best Stocks To Buy And Watch? Start Here

The stock has an 86 EPS Rating, meaning its recent quarterly and annual earnings growth tops 86% of all stocks.

Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.

In Q3, the company posted 4% earnings growth. Top line growth fell to 18%, down from 21% in the prior quarter.

McKesson holds the No. 2 rank among its peers in the Medical-Wholesale Drugs industry group. is the No. 1-ranked stock within the group.

This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.